SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : SNOA (MC $23 M) (Cash $13 M) Lots of Marketed Products
SNOA 3.640-0.1%12:59 PM EST

 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
From: BioHero10/18/2017 10:48:57 AM
   of 11
 
This ultra low float stock is brutally undervalued which tradingjust a few pennies above Book Value .Fantastic entry point here this stock is definitely one of the cheapest in the Pharma Sector .GL

Sonoma Pharma (Nasdaq: SNOA)

Marketcap: 19.6 Million
Cash: $12.6 Million
Price: $4.55

Book Value: $4.32
Annual Revenue on track to hit $16 Million

Shares Out : 4.3 Million

Stonegate Capital Partners Updates Coverage on Sonoma Pharmaceuticals, Inc. (Nasdaq: SNOA) ..October 18, 2017
pr.report

As of 6/30/17, the Company reported $3.8M in total revenue for Q1 FY18, with product revenues up 49% year-over-year driven by growth in US dermatology and acute care markets and in products sold to new owner of Latin American assets, and with approximately $12.6M in cash on hand and minimal debt. On an EV/R basis, Sonoma currently trades at 0.2x vs. the median of its peers at 34.5x based on FY18 estimates. In addition, companies in the dermatology space have been acquired at a median EV/R multiple of 3.6x. See full report for additional details.

Sonoma Pharmaceuticals Announces U.S. Commercialization of Loyon® for Relief of Scaling, Burning and Itching Associated with Various Dermatoses Including Seborrhea and Seborrheic Dermatitis

finance.yahoo.com
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext